- Home
- RMCO vs BIAF Comparison
RMCO vs BIAF Comparison
Compare RMCO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- BIAF
- Stock Information
- Founded
- RMCO 2021
- BIAF 2014
- Country
- RMCO United States
- BIAF United States
- Employees
- RMCO N/A
- BIAF N/A
- Industry
- RMCO Multi-Sector Companies
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RMCO Miscellaneous
- BIAF Health Care
- Exchange
- RMCO Nasdaq
- BIAF Nasdaq
- Market Cap
- RMCO 14.9M
- BIAF 12.2M
- IPO Year
- RMCO N/A
- BIAF 2022
- Fundamental
- Price
- RMCO $1.28
- BIAF $0.29
- Analyst Decision
- RMCO
- BIAF Hold
- Analyst Count
- RMCO 0
- BIAF 1
- Target Price
- RMCO N/A
- BIAF N/A
- AVG Volume (30 Days)
- RMCO 18.0K
- BIAF 11.2M
- Earning Date
- RMCO 08-14-2025
- BIAF 08-13-2025
- Dividend Yield
- RMCO N/A
- BIAF N/A
- EPS Growth
- RMCO N/A
- BIAF N/A
- EPS
- RMCO N/A
- BIAF N/A
- Revenue
- RMCO $1,568,212.00
- BIAF $8,809,228.00
- Revenue This Year
- RMCO N/A
- BIAF N/A
- Revenue Next Year
- RMCO N/A
- BIAF $20.00
- P/E Ratio
- RMCO N/A
- BIAF N/A
- Revenue Growth
- RMCO 204.08
- BIAF 78.40
- 52 Week Low
- RMCO $0.74
- BIAF $0.16
- 52 Week High
- RMCO $1.32
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- RMCO 62.27
- BIAF 50.96
- Support Level
- RMCO $1.19
- BIAF $0.22
- Resistance Level
- RMCO $1.30
- BIAF $0.46
- Average True Range (ATR)
- RMCO 0.06
- BIAF 0.04
- MACD
- RMCO 0.02
- BIAF 0.01
- Stochastic Oscillator
- RMCO 80.00
- BIAF 30.51
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.